Full-Time

Medical Advisor

Aesthetics

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

No salary listed

Sydney NSW, Australia

Hybrid

Three office days per week are required: Tuesday, Wednesday, and Thursday. Travel throughout Australia and New Zealand is expected.

Bachelor's, Master's, PhD

Category
Biology & Biotech
Required Skills
PowerPoint/Keynote/Slides

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • A science degree is required.
  • A minimum of 5 years of post-qualification work experience is required, including experience in a pharmaceutical or medical-related industry.
  • A minimum of 2 years of experience working in a medical affairs team in the medical device or pharmaceutical science industry is required.
  • Strategic thinking and leadership skills are required.
  • Advanced stakeholder engagement and influencing skills are required.
  • Excellent scientific communication and presentation skills are required.
  • Strong analytical skills, including the ability to critically evaluate and effectively communicate key clinical data, are required.
  • The ability to quickly learn and communicate clinical and non-clinical technical information effectively to individuals with varying degrees of scientific acumen is required.
  • The ability to work cross-functionally in a matrix structure while supporting multiple stakeholders is required.
  • A high level of professional integrity and understanding of compliance requirements is required.
  • The ability to work independently with sound judgment and accountability is required.
  • Strong project management skills are required.
  • Strong listening skills, including the ability to capture and synthesize insights, are required.
  • Intermediate Microsoft Suite skills, particularly PowerPoint, are required.
  • The ability to travel approximately 50% of the work time throughout Australia and New Zealand is required.
Responsibilities
  • Work closely with the Associate Director, Medical Affairs, ANZ, to define Medical Affairs priorities, strategy, and execution plans for the therapeutic area.
  • Lead the development and implementation of the Medical Affairs plan in alignment with regional priorities, the International Therapeutic Lead, and local business objectives.
  • Translate medical strategy into prioritised field activities and stakeholder engagement plans across Australia and New Zealand.
  • Be accountable for the delivery, quality, and impact of Medical Affairs initiatives within the assigned therapeutic area.
  • Develop understanding of the Australia and New Zealand clinical landscape, including treatment pathways, standards of care, stakeholder needs, unmet medical needs, and emerging scientific trends, to inform strategy and execution.
  • Provide medical leadership and strategic direction to Medical Science Liaison activities and other Medical Affairs initiatives.
  • Act as a medical resource for internal stakeholders by providing objective medical insight and perspective for compliant business decisions.
  • Lead non-promotional scientific exchange with healthcare professionals regarding Allergan Aesthetics products, supporting evidence, appropriate use, and relevant therapeutic areas.
  • Lead and facilitate scientific education and training for physicians and other healthcare professionals.
  • Develop, plan, and deliver medical education initiatives, speaker programs, advisory activities, scientific meetings, and other external engagements in accordance with applicable policies and local requirements.
  • Set the scientific direction and medical content for educational activities, ensuring materials and presentations are medically accurate, balanced, evidence-based, and compliant.
  • Serve as a senior scientific resource for healthcare professionals, key opinion leaders, and other external stakeholders.
  • Support physicians’ expertise and confidence in the appropriate use of Allergan Aesthetics products through scientific education and professional development initiatives.
  • Maintain therapeutic-area expertise and current knowledge of relevant scientific, clinical, and practice developments.
  • Identify, prioritise, and engage key opinion leaders, researchers, physicians, nurses, administrators, specialty societies, and other stakeholders influencing the scientific and clinical landscape.
  • Develop and execute strategic key opinion leader engagement plans.
  • Lead stakeholder and territory planning across Australia and New Zealand.
  • Lead local, regional, and national scientific activities with key stakeholders, including objectives, agendas, engagement plans, and success measures.
  • Identify emerging leaders with relevant specialty interests and lead educational initiatives to foster long-term relationships and support development of the therapeutic area.
  • Maintain relationships with physicians, administrators, and representatives of relevant specialty societies.
  • Interpret and communicate stakeholder feedback, clinical practice insights, and external engagement outcomes to inform Medical Affairs strategy and planning.
  • Manage a predominantly customer-facing role, with approximately 65% of time dedicated to external stakeholder interaction.
  • Keep current on scientific, clinical, and market developments in Australia and New Zealand, the broader Asia-Pacific region, and globally.
  • Attend key medical congresses and scientific forums locally.
  • Gather and communicate external insights, competitor intelligence, and scientific observations to inform Medical Affairs strategy and planning.
  • Contribute accurate and balanced medical advice to the scientific development of promotional and educational materials where appropriate and compliant.
  • Report adverse events within 24 hours in accordance with Allergan policies and procedures.
  • Participate in AbbVie workplace health and safety programs, adhere to policies, and promote a safe work environment.
  • Adhere to Allergan and AbbVie codes of conduct and compliance processes.
  • Perform other administrative duties as requested.
Desired Qualifications
  • Bachelor of Pharmacy, Nursing, Doctor of Pharmacy, Master of Science, or Doctor of Philosophy is preferred.
  • Overseas education or work experience is desirable.
  • Experience in clinical research, including Phase IV studies, is desirable.
  • Previous experience in a customer-facing role is highly regarded.

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $16.99 billion, up 10.2%, with EPS of $3.65.
  • AbbVie raised 2026 guidance to $13.87-$14.07 after broad strength across immunology and neuroscience.
  • Rinvoq and Skyrizi both grew above 23% operationally, showing durable post-Humira momentum.

What critics are saying

  • Humira sales fell 36.1% in Q2 2026; biosimilars keep compressing cash flows.
  • Imbruvica dropped 29.4% in Q2 2026, exposing oncology weakness and IRA pricing damage.
  • Apogee dilutes adjusted EPS through 2027; if Skyrizi stalls, AbbVie loses its bridge.

What makes AbbVie unique

  • Skyrizi and Rinvoq delivered $8.0 billion in Q2 2026, replacing Humira.
  • AbbVie completed Apogee on September 3, 2026, adding long-acting immunology assets.
  • Etentamig posted 74% response in Phase 3 multiple myeloma, broadening oncology optionality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
Yahoo Finance
Sep 10th, 2026
AbbVie shifts focus from declining Humira to $8B Skyrizi and Rinvoq growth engines

AbbVie has dramatically shifted its focus away from Humira, its once-flagship drug now facing biosimilar competition. On the company's July 2026 earnings call, Humira received just one sentence, noting global sales of $706 million, down 36.1% operationally but in line with expectations. This marks a stark change from previous quarters when management detailed the reasons behind Humira's decline, including biosimilar competition and molecule compression in the US market. AbbVie now emphasises growth drivers instead. Skyrizi generated $5.5 billion in Q2 2026, whilst Rinvoq exceeded $2.5 billion, both growing above 20% operationally. The company also acquired Apogee Therapeutics in September 2026. Despite the reduced attention, Humira still contributes approximately 4% of AbbVie's quarterly revenue of nearly $17 billion, though management no longer publicly projects its ultimate decline trajectory.

Yahoo Finance
Sep 9th, 2026
Billionaire hedge fund manager doubles down on AbbVie and Costco dividend stocks

Israel Englander's Millennium Management more than doubled its stakes in AbbVie and Costco during the second quarter. AbbVie's revenue grew 10.2% year-over-year to $17 billion in Q2, driven by immunology drugs Skyrizi and Rinvoq. The company recently acquired Apogee Therapeutics for $10.9 billion in cash and is developing ABBV-295, a monthly weight-loss treatment. AbbVie is a Dividend King with over 50 consecutive years of payout increases. Costco's Q3 fiscal 2026 revenue rose 11.6% to $70.5 billion, with comparable sales up 9.8%. The company has raised dividends for 22 consecutive years. However, Costco shares are down 4% over the past year whilst trading at 40.8 times forward earnings, above the consumer staples average of 21.6 times. Both companies maintain strong fundamentals despite different market challenges.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INSURASALES
Sep 5th, 2026
Manufacturers Life Insurance buys $655M stake in AbbVie as institutions boost pharma holdings

The Manufacturers Life Insurance Company acquired a $655.27 million stake in AbbVie Inc., according to its latest SEC Form 13F filing. Other institutional investors also increased their positions significantly during the same period. Norges Bank acquired a new $5.87 billion position, whilst Wellington Management Group boosted its holdings by 457.4%. AbbVie reported quarterly earnings per share of $3.65, exceeding forecasts, with revenue growth of 10.2% year over year. The company generated $16.99 billion in revenue last quarter, surpassing expectations. Equity analysts maintain a bullish outlook. Barclays, Wolfe Research, and BMO Capital Markets each set price targets of $300, with ratings of "overweight" or "outperform". The consensus rating is "Moderate Buy". Institutional investors currently hold 70.23% of AbbVie's shares, reflecting confidence in the biopharmaceutical company's strategy and performance.

PharmTech
Sep 4th, 2026
AAPS PharmSci 360: CMC strategies, part 1.

AAPS PharmSci 360: CMC strategies, part 1. In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy. PharmTech spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy. Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions. Singh cautioned, however, that companies must build "risk justification muscle" rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators. Rumondor addressed the pressure to compress development timelines. He argued the real question isn't whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor. About the speakers. Alfred Rumondor, PhD, is Director, Development Sciences Licensing and Acquisitions, at AbbVie. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.